878757-08-5

Usage

Uses

Used in Pharmaceutical Industry:
THANDRA is used as a research compound for the development of novel treatments for attention-deficit hyperactivity disorder (ADHD) due to its ability to selectively release dopamine and norepinephrine in the brain. Its psychoactive and stimulating effects make it a promising candidate for further investigation into its therapeutic potential.
Used in Neuroscience Research:
In the field of neuroscience, THANDRA serves as a valuable tool for studying the effects of dopamine and norepinephrine on brain function and behavior. Its potent and selective action on these neurotransmitters allows researchers to gain insights into the underlying mechanisms of various neurological and psychiatric conditions.
Used in Regulatory and Legal Frameworks:
Due to its potential for abuse and addiction, THANDRA is used as a case study in the development and implementation of regulatory and legal frameworks to control the distribution and use of substances with high potential for misuse. This helps ensure public safety and prevent the negative consequences associated with substance abuse.

Upstream product

• 116817-12-0 N,N-dimethyl-3-(1-naphthalenyloxy)-3-(thien-2-yl)propanamine oxalate 
• 116817-11-9 N,N-dimethylamino-3-(1-naphthanyloxy)-3-(2-thienyl)-1-propanamine 
• 321-38-0 1-Fluoronaphthalene 
• 132335-44-5 (S)-3-dimethylamino-1-(2-thienyl)propan-1-ol 

Downstream Products

• 116539-60-7 (R)-Duloxetine 
• 932013-45-1 (R)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate 
• 132335-47-8 (S)-N,N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine oxalate 
• 910138-96-4 (R)-(-)-N-methyl-3-(1-napthalenyloxy)-3-(2-thienyl)propanamine hydrochloride 
• 116817-11-9 N,N-dimethylamino-3-(1-naphthanyloxy)-3-(2-thienyl)-1-propanamine 

Relevant academic research and scientific papers

An investigation on key parameters that influence the synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propylamine: A key intermediate for duloxetine

This document highlights the systematic study of influencing factors such as temperature, base, catalyst, and solvent volume in the synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propylamine oxalate 11a, without affecting the chiral

Process for the Preparation of 1-Naphthol Mixed Ethers and Intermediates of Crystalline Forms of (+) and (-)-Duloxetine

The invention relates to a process for the preparation of duloxetine (1a), comprising the reaction between 1-fluoronaphthalene and 3-N,N-dimethylamino-1-(2-thienyl)-propan-1-ol in the presence of 1,3-dimethyl-2-oxo-hexahydropyrimidine (DMPU) as the solvent; a method for the identification of duloxetine enantiomers and for the determination of its optical purity is also disclosed.

PROCESS FOR THE PREPARATION OF DULOXETINE

The invention relates to a process for the preparation of duloxetine (1a), comprising the reaction between 1-fluoronaphthalene and 3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol in the presence of l,3-dimethyl-2-oxo-hexahydropyrimidine (DMPU) as the solvent; a method for the identification of duloxetine enantiomers and for the determination of its optical purity is also disclosed.

A NOVEL PROCESS FOR THE PREPARATION OF (S)-(+)-N,N-DIMETHYL-3-(1-NAPHTHALENYLOXY)-3-(2-THIENYL)PROPANAMINE, A DULOXETINE INTERMEDIATE

Provided is a process for preparing a duloxetine intermediate,(S)-(+)-N,N-Dimethyl-3-(1- naphthalenyloxy)-3-(2-thienyl)propanamine (DNT), and its conversion to duloxetine or a pharmaceutically acceptable salt thereof.